Podcast appearances and mentions of George D Demetri

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:Mechanisms of acquired resistance to TRK inhibitor therapyClinical trial data on the second-generation inhibitors selitrectinib and repotrectinibSafety profiles of first- vs second-generation TRK inhibitorsPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental TherapeuticsDirector, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, ThoracicMemorial Sloan Kettering Cancer CenterNew York, New YorkLink to full program, including downloadable slides:https://bit.ly/2YFIPfr

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:Basket trials leading to FDA approvals of larotrectinib and entrectinibCurrent pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLCSequencing treatment with TRK inhibition in patients with solid tumorsClinically relevant similarities and differences between larotrectinib and entrectinibPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental TherapeuticsDirector, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, ThoracicMemorial Sloan Kettering Cancer CenterNew York, New YorkLink to full program, including downloadable slidesets:https://bit.ly/2YFIPfr

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies for testing. Topics include:Differences between NTRK fusions vs gene mutationsFrequency of NTRK fusions by age and tumor typeWhen to test patients for NTRK fusions and interpreting reportsMethods of testing: multiplex gene testing, next-generation sequencing of DNA vs RNA, immunohistochemistry, and liquid biopsyPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental TherapeuticsDirector, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, ThoracicMemorial Sloan Kettering Cancer CenterNew York, New YorkLink to full program:https://bit.ly/2YFIPfrLink to slideset based on this podcast:https://bit.ly/3amgU6w 

Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options. Upon completion of this activity, participants should be better able to: Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers, Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers, Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors, Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others.

Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options. Upon completion of this activity, participants should be better able to: Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers, Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers, Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors, Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others.

Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options. Upon completion of this activity, participants should be better able to: Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers, Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers, Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors, Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others.

Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options. Upon completion of this activity, participants should be better able to: Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers, Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers, Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors, Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others.

Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options. Upon completion of this activity, participants should be better able to: Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers, Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers, Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors, Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others.

Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options. Upon completion of this activity, participants should be better able to: Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers, Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers, Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors, Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others.

Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options. Upon completion of this activity, participants should be better able to: Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers, Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers, Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors, Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others.

Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options. Upon completion of this activity, participants should be better able to: Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers, Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers, Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors, Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others.

In this episode, George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer questions about NTRK fusion testing and TRK inhibitor therapy for patients with advanced solid tumors, with topics including:Best practices in testing for NTRK fusions in solid tumorsOptimal use of approved TRK inhibitorsKey adverse events with TRK inhibitors and management strategiesEmerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agentsPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental Therapeutics  Director, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, Thoracic OncologyMemorial Sloan Kettering Cancer CenterNew York, New YorkPashtoon Kasi, MDAssistant ProfessorCollege of Medicine and OncologyHolden Comprehensive Cancer CenterUniversity of IowaIowa City, IowaContent based on an online CME program supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Genentech.Link to full program: https://bit.ly/2PN0BWh

The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond

The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond

The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond

The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond

The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond

The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond

The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond

The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond

George D. Demetri, MD, discusses the evolving treatment landscape of advanced soft tissue sarcoma.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with George D Demetri, MD conducted by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Featuring interviews with George D Demetri, MD, Johanna C Bendell, MD, Norman Wolmark, MD and Ghassan Abou-Alfa, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with George D Demetri, MD conducted by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Featuring interviews with George D Demetri, MD, Johanna C Bendell, MD, Norman Wolmark, MD and Ghassan Abou-Alfa, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.